Greensboro’s Carolina Liquid Chemistries to Distribute Analyzer to Vet Market

CLC logo
.

Carolina Liquid Chemistries Corp. of Greensboro has signed a semi-exclusive agreement to distribute a portable chemistry analyzer for the U.S. veterinary market.

The company will distribute the Seamaty SMT-120VP Veterinary Automated Chemistry Analyzer, a compact, fully automatic chemistry, electrolyte, immunoassay and coagulation analyzer for animal health diagnosis.

With a footprint of only 7.6 by 8.8 inches and only 8.8 pounds, the analyzer offers portability and space savings, the company said in a news release.

he Seamaty SMT-120VP
The Seamaty SMT-120VP. -- CLC photo

“The incredible portability of the SMT-120VP allows the analyzer to be taken to a large animal’s location rather than having to haul a large animal to a testing facility,” said Patricia Shugart, chief operating officer of Carolina Liquid Chemistries.

The machine’s Android operating system with built-in intelligent quality control makes it easy to achieve accurate, reliable results for animals of all sizes, yielding chartable results after 12 minutes. Freeze-dried reagents offer fifteen-month shelf life, and all fluids are contained within consumable rotors, eliminating the need for internal pumps, valves, and other vulnerable parts.

The analyzer is made by Chengdu Seamaty Technology Co., based in Chengdu, Sichuan Province, China. Seamaty provides medical equipment to the medical and veterinary diagnostic industry worldwide.

“Carolina Liquid Chemistries Corp. is known for its chemistry analyzers and reagents for over twenty-five years in the human clinical market,” Shugart said. “We recognized the need for cost-effective and convenient options in the veterinary market.”

Founded in 1994, Carolina Liquid Chemistries is a veteran-owned, ISO-certified, FDA-registered manufacturer, re-packager, re-labeler and value-added reseller of chemistry systems and reagents, as well as COVID-19 tests and supplies. It has served over 2,000 customers worldwide.

The company has responded to the COVID-19 pandemic by providing various testing products and supplies to market under the FDA’s Emergency Use Authorization.

Barry Teater, NCBiotech Writer
scroll back to top of page